Acadia Pharma (ACAD) Misses Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
February 28, 2022 4:05 PM EST- Full year 2021 net sales grew to $484.1 million, a 10% increase over 2020
- Resubmitted sNDA for pimavanserin for the treatment of Alzheimer's disease psychosis
- Delivered positive top-line results from the pivotal Phase 3 Lavender trial evaluating trofinetide for the treatment of Rett syndrome
SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced financial results for the fourth quarter and full year ended December 31, 2021.
Acadia delivered strong fourth quarter and full year results with an increase in net sales of 10... More
